Major Threat to Malaria Control Programs by Plasmodium falciparum Lacking Histidine-Rich Protein 2, Eritrea
Araia Berhane, Karen F. Anderson, Selam Mihreteab, Karryn Gresty, Eric Rogier, Salih Mohamed, Filmon Hagos, Ghirmay Embaye, Anderson Chinorumba, Assefash Zehaie, Simone Dowd, Norman C. Waters, Michelle L. Gatton, Venkatachalam Udhayakumar, Qin Cheng
, and Jane Cunningham
Author affiliations: Ministry of Health, Asmara, Eritrea (A. Berhane, S. Mihreteab, S. Mohamed, F. Hagos, G. Embaye); Australian Defence Force Malaria and Infectious Disease Institute, Brisbane, Queensland, Australia (K. Anderson, K. Gresty, S. Dowd, Q. Cheng); QIMR–Berghofer Medical Research Institute, Brisbane (K. Anderson, K. Gresty, S. Dowd, Q. Cheng); Centers for Disease Control and Prevention, Atlanta, Georgia, USA (E. Rogier, V. Udhayakumar); World Health Organization, Geneva, Switzerland (A. Chinorumba, J. Cunningham); World Health Organization, Asmara (A. Zehaie); Walter Reed Army Institute of Research, Silver Spring, Maryland, USA (N.C. Waters); Queensland University of Technology, Brisbane (M.L. Gatton)
Figure 3. Plasmodium falciparum HRP2 antigen levels in relation to presence or absence of pfhrp2/pfhrp3 genes and HRP2-based malaria RDT results, Eritrea. Horizontal lines indicate means, and error bars indicate SDs. HRP2, histidine-rich protein 2; pfhrp, P. falciparum histidine-rich protein; RDT, rapid diagnostic test; – negative; +, positive.
Page created: February 15, 2018
Page updated: February 15, 2018
Page reviewed: February 15, 2018
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.